Tepnel to build contract analysis facility
UK-based international life sciences products and services group Tepnel Life Sciences has completed the purchase of 1.7 acres of land in Livingston, Scotland, for the construction of a dedicated pharmaceutical, protein and genomic analysis facility.
UK-based international life sciences products and services group Tepnel Life Sciences has completed the purchase of 1.7 acres of land in Livingston, Scotland, for the construction of a dedicated pharmaceutical, protein and genomic analysis facility.
The 18,000ft2 state-of-the-art laboratory will allow the company to consolidate its existing pharmaceutical services business into a single location with its primary function being the analysis of therapeutic proteins including recombinant and affinity purified proteins for use as therapeutic agents and vaccines. It will also expand it pharmacogenomics capabilities to include high throughput genotyping and other genomic analysis techniques.
'This is an important milestone in our long-term strategy to provide the most competitive platform for our existing pharmaceutical analysis services. It will also allow us to continue the successful development of some of our most specialized products and services in high growth areas such as pharmacogenomics and new generations of vaccines,' said Ben Matzilevich, Tepnel's ceo.
'This facility will enable our Research Products & Services group to use our mass spectrometry capabilities in building our position in the rapidly evolving therapeutic protein market. Additionally, we shall expand our capabilities in bio- and immunoassays of these therapeutic molecules for our pharmaceutical and biotechnology customers.'